These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22498014)

  • 21. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome.
    Lambrinoudaki I
    Maturitas; 2011 Jan; 68(1):13-6. PubMed ID: 20943333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS).
    Macut D; Micić D; Cvijović G; Sumarac M; Kendereski A; Zorić S; Pejković D
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1353-59; discussion 1365. PubMed ID: 11964034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary (Stein-Leventhal) syndrome: etiology, complications, and treatment.
    Hoyt KL; Schmidt MC
    Clin Lab Sci; 2004; 17(3):155-63. PubMed ID: 15314890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
    Brzozowska MM; Ostapowicz G; Weltman MD
    J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
    Osibogun O; Ogunmoroti O; Michos ED
    Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
    Sorensen MB; Franks S; Robertson C; Pennell DJ; Collins P
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):655-9. PubMed ID: 17054469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycystic ovary syndrome in adolescence.
    Blank SK; Helm KD; McCartney CR; Marshall JC
    Ann N Y Acad Sci; 2008; 1135():76-84. PubMed ID: 18574211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women.
    Anaforoglu I; Algun E; Incecayir O; Ersoy K
    Metab Syndr Relat Disord; 2011 Oct; 9(5):375-80. PubMed ID: 21657888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing cardiovascular risk in women with polycystic ovary syndrome: more than the sum of its parts?
    Chang AY; Wild RA
    Semin Reprod Med; 2009 Jul; 27(4):299-305. PubMed ID: 19530063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive clinical management of polycystic ovary syndrome.
    Setji TL; Brown AJ
    Minerva Med; 2007 Jun; 98(3):175-89. PubMed ID: 17592439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.
    Araujo Penna I; Canella PR; Vieira CS; Silva de Sá MF; dos Reis RM; Ferriani RA
    Fertil Steril; 2007 Aug; 88(2):519-22. PubMed ID: 17418836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Not all women diagnosed with PCOS share the same cardiovascular risk profiles.
    Jovanovic VP; Carmina E; Lobo RA
    Fertil Steril; 2010 Aug; 94(3):826-32. PubMed ID: 19501355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Puberty and polycystic ovary syndrome.
    Witchel SF
    Mol Cell Endocrinol; 2006 Jul; 254-255():146-53. PubMed ID: 16750596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome.
    Targher G; Zoppini G; Bonora E; Moghetti P
    Semin Thromb Hemost; 2014 Jul; 40(5):600-18. PubMed ID: 25000958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician.
    Lorenz LB; Wild RA
    Clin Obstet Gynecol; 2007 Mar; 50(1):226-43. PubMed ID: 17304038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia.
    Hahn S; Tan S; Elsenbruch S; Quadbeck B; Herrmann BL; Mann K; Janssen OE
    Horm Metab Res; 2005 Jul; 37(7):438-44. PubMed ID: 16034717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.
    Carmina E; Orio F; Palomba S; Longo RA; Lombardi G; Lobo RA
    Fertil Steril; 2005 Aug; 84(2):413-9. PubMed ID: 16084883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment.
    Tan S; Hahn S; Janssen OE
    Panminerva Med; 2005 Dec; 47(4):211-7. PubMed ID: 16489320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.
    Soares GM; Vieira CS; de Paula Martins W; Dos Reis RM; de Sá MF; Ferriani RA
    Int J Clin Pract; 2009 Jan; 63(1):160-9. PubMed ID: 18795969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.